Passing 340B drug discounts to patients with COPD so they can buy inhalers at a much lower cost yielded positive outcomes both for the patients and the hospitals that serve them, new research shows.

Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings

July 7, 2023 Tom Mirga, Editor at Large Views

Two new studies—one by pharmacists at Ascension Via Christi health system in Kansas, the other by drug industry consulting and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Site Footer Live